An open randomised study of the efficacy of standard radiotherapy with and without the addition of SRL172 (Mycobacterium vaccae) in the treatment of patients with small cell lung cancer (SIRON 13)

Submission date 19/08/2002	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 19/08/2002	Overall study status Completed	 [] Statistical analysis plan [X] Results
Last Edited 26/03/2020	Condition category Cancer	[_] Individual participant data

Plain English summary of protocol Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr - -

Contact details UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers SIRON 13

Study information

Scientific Title

An open randomised study of the efficacy of standard radiotherapy with and without the addition of SRL172 (Mycobacterium vaccae) in the treatment of patients with small cell lung cancer (SIRON 13)

Study objectives Not provided at time of registration

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Not specified

Study type(s) Not Specified

Participant information sheet

Health condition(s) or problem(s) studied Lung (small cell)

Interventions

Standard chemotherapy (as per protocol)
 Standard chemotherapy + SRL172 injections (as per protocol)

Intervention Type

Other

Phase Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures Not provided at time of registration

Overall study start date

01/01/2000

Completion date

31/12/2001

Eligibility

Key inclusion criteria

1. Patients should be aged at least 18 years with histologically and/or cytologically confirmed unresectable small cell lung cancer, which includes limited or extensive stage disease 2. There should be presence of measurable or evaluable disease

3. Patients should be World Health Organisation (WHO) performance status 0-2

4. Serum creatinine <140 micromol/l or creatinine clearance >50 ml/min (if serum creatinine 120-

140 micromol/l) if receiving cisplatin. If receiving carboplatin, creatinine clearance >20ml/min 5. Life expectance >3 months

6. Written informed consent

Participant type(s) Patient

Age group Adult

Lower age limit 18 Years

Sex Not Specified

Target number of participants Not provided at time of registration

Key exclusion criteria Not provided at time of registration

Date of first enrolment 01/01/2000

Date of final enrolment 31/12/2001

Locations

Countries of recruitment

England

United Kingdom

Study participating centre UKCCCR Register Co-ordinator London United Kingdom NW1 2DA

Sponsor information

Organisation UK Co-ordinating Committee for Cancer Research (UKCCCR)

Sponsor details MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Sponsor type Government

ROR https://ror.org/054225q67

Funder(s)

Funder type Charity

Funder Name Cancer organisations (UK)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	01/06/2004	26/03/2020	Yes	No